Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa.

The long-term safety and immunogenicity of a polyvalent Pseudomonas aeruginosa conjugate vaccine was evaluated in 30 noncolonized cystic fibrosis patients. Four doses were administered over 3 years, and patients were followed for a mean of 38 months. No acute or long-term adverse effects were noted. Immunization engendered a significant antibody response to all vaccine components. A decline in titers during year 3 of observation was associated with a marked rise in the isolation of P. aeruginosa. This organism was isolated repeatedly from the respiratory tract of 4 patients and only once from 7 patients. The remaining patients were repeatedly culture-negative. Only 1 patient showed clinical deterioration associated with multiple isolations of P. aeruginosa.

[1]  B. Tümmler,et al.  Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis , 1993, The Lancet.

[2]  Zentrum Biochemie.  Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis , 1993 .

[3]  S. Cryz,et al.  Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients. , 1992, The Journal of infectious diseases.

[4]  S. Cryz,et al.  Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis , 1991, The Lancet.

[5]  N. Høiby,et al.  Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment , 1991, The Lancet.

[6]  U. Schaad,et al.  Serotype-Specific Serum IgG Antibodies to Lipopolysaccharides of Pseudomonas aeruginosa in Cystic Fibrosis: Correlation to Disease, Subclass Distribution, and Experimental Protective Capacity , 1990, Pediatric Research.

[7]  N. Høiby,et al.  Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis , 1990, Journal of clinical microbiology.

[8]  R. Bram,et al.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. , 1989, The Journal of clinical investigation.

[9]  H. Van Bever,et al.  Immune complexes and Pseudomonas aeruginosa antibodies in cystic fibrosis. , 1988, Archives of disease in childhood.

[10]  R. S. Conrad,et al.  Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa lung infection in cystic fibrosis , 1988, Infection and immunity.

[11]  S. Cryz,et al.  Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans , 1988, Infection and immunity.

[12]  G. Pier,et al.  Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients , 1986, Journal of clinical microbiology.

[13]  J. Hiller,et al.  Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results. , 1984, Archives of disease in childhood.

[14]  M. Marks.  The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. , 1981, The Journal of pediatrics.